Boston Scientific Q4 Revenue Climbs 15.9% to $5.29 Billion but Shares Drop 53%
Boston Scientific reported Q4 revenues of $5.29 billion, a 15.9% year-on-year increase that matched consensus estimates, led by robust organic growth. Shares have slid 53% to $74.35 since the report, underperforming peers despite delivering the fastest revenue growth in the diversified medical devices group.
1. Q4 Financial Results
Boston Scientific posted Q4 revenues of $5.29 billion, up 15.9% year-over-year, matching consensus estimates and leading the diversified medical devices group in growth.
2. EPS Guidance and Market Reaction
The company narrowly beat analysts' organic revenue forecasts but issued EPS guidance slightly below expectations, triggering a 53% decline in its share price to $74.35 since the earnings release.
3. Comparative Performance
Despite delivering the fastest revenue growth among five diversified medical device peers, Boston Scientific underperformed in the market as investors weighed concerns over profitability margins and future guidance.